Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Imdelltra-Imfinzi Combo Meets OS Goal in Frontline SCLC Maintenance

Guavy AI Editorial Team
Instruments
AMGN
Share

Amgen's Imdelltra (tarlatamab) in combination with AstraZeneca's Imfinzi (durvalumab) has met its primary overall survival endpoint in a phase III trial for first-line maintenance treatment of adults with extensive-stage small-cell lung cancer (ES-SCLC).

The study aimed to assess the efficacy and safety of this immunotherapy combination as a maintenance treatment in patients with ES-SCLC.

The results showed that Imdelltra-Imfinzi met the primary overall survival goal, but no further details were provided on specific survival times or percentage increases.

More on Stocks

Stocks just now

Amgen Irish Open 2026 Broadcast Details Announced

Stocks 2m ago

Stepping Away from Corporate Life: The Uncomfortable Truth About Freedom

Stocks 5m ago

Amazon, Alphabet Spend $420 Billion on Data Centers Amid Rapid Growth

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy